ArticleViruses2026
Trimeric Class I Viral Fusion Protein Vaccine Immunogens Using a Trimeric Autotransporter in a Killed Whole-Cell Bacteria Vaccine Platform: Applications to HIV MPER.
Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTrimeric envelope-proximal domains in viral class I fusion proteins are conserved targets of broadly neutralizing antibodies (bNAbs), but it has proven difficult to develop vaccines against those targets. The HIV-1 gp41 membrane-proximal external region (MPER) is one such target. Induction of a neutralizing response likely depends on the immunogen having a close-to-native structure.
methodsNative sequence MPER was displayed on genome-reduced bacteria as a coiled-coil homotrimer using a
resultsTrimer stabilization improved MPER exposure, but immunogen visibility alone did not predict neutralization. After three immunizations, neutralizing activity was detected only in the most extensively engineered vaccine, which neutralized tier 2 virus CNE55. After five immunizations, the same vaccine also neutralized the tier 2 virus 25710-2.43. A further design modification that included an extended Hia-derived spacer increased MPER exposure and antibody binding, with neutralization detected against MN.3, X1632_S2_B10, and 25710-2.43 viruses in subsets of animals.
conclusionsAs a proof-of-concept, native-sequence MPER can induce detectable, though modest and virus-dependent, HIV-1 neutralizing activity when displayed in a carefully controlled trimeric bacterial surface-display platform. The results show that MPER vaccine performance depends not only on antigen exposure, but also on multimeric organization, immunomodulatory context, and antigen-scaffold geometry. Analogous coiled-coil trimeric bacterial surface display immunogens may inform vaccine development for stem/stalk regions of other Class I fusion protein viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.